Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Next Previous
Trial Profile

A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iscalimab (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Acronyms TWINSS
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 06 Aug 2024 Primary endpoint has been met. (Change in EULAR Sjgren Syndrome Disease Activity Index (ESSDAI) score from baseline at 24 weeks as compared to placebo)
  • 06 Aug 2024 Results published in the Internet Document
  • 15 Jun 2024 Results(n=163) evaluating the safety and efficacy of iscalimab in SjD patients, presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top